



an Open Access Journal by MDPI

## Plant-Based Bioactive Molecules as Anticancer Drugs/Formulations

Guest Editors:

**Dr. Minaxi Sharma**

Haute Ecole Provinciale de  
Hainaut-Condorcet, Rue Paul  
Pastur, 7800 Ath, Belgium

**Dr. Deepti Diwan**

Washington University School of  
Medicine, Saint Louis, MO 63110,  
USA

Deadline for manuscript  
submissions:

**closed (29 February 2024)**

### Message from the Guest Editors

Dear Colleagues,

Recognizing the loss of millions of cancer patients annually, negating malignant metastatic conditions remains paramount. Accumulating evidence has shown that plant-derived bioactive compounds are promising candidates for inhibition of tumor growth and metastasis, which has a significant influence on tumor progression, the microenvironment, and drug resistance in multifarious cancers. The primary objective of this SI is to describe what we know to date about plant-derived active compounds, application strategies as extracts/drugs or nanoformulations, pharmacologic action, molecular or specific target delivery and bioavailability as cancer therapeutics, and recent trends and gaps in phytochemical-based anticancer drug discovery. Plant-based bioactive molecules that need a special chemical formula in order to determine their anticancer efficacy will be considered. In summary, this SI will describe the promising application of phytochemicals or phytochemotherapy and recent technological interventions against cancer that have the potential to enhance therapeutic effectiveness, reduce the associated side effects, and improve clinical outcomes.



[mdpi.com/si/162874](https://mdpi.com/si/162874)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI